 BeyondSpring Incs NASDAQ:BYSI lead candidate plinabulin is likely to receive approval around the Nov. 30 PDUFA date for chemotherapy-induced neutropenia CIN, according to Baird. The BeyondSpring Analyst: Joel Beatty initiated coverage of BeyondSpring with an Outperform rating and a price target of 50. 